Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, United States.
Department of Neurology, ISMMS, New York, NY, United States; Institute for HealthCare Delivery Science, Department of Population Health Science and Policy, ISMMS, New York, NY, United States.
Seizure. 2024 Jan;114:33-39. doi: 10.1016/j.seizure.2023.11.018. Epub 2023 Nov 26.
Coronavirus disease 2019 (COVID-19) is associated with high rates of mortality and morbidity in older adults, especially those with pre-existing conditions. There is little work investigating how neurological conditions affect older adults with COVID-19. We aimed to compare in-hospital outcomes, including mortality, in older adults with and without epilepsy.
This retrospective study in a large multicenter New York health system included consecutive older patients (age ≥65 years) either with or without epilepsy who were admitted with COVID-19 between 3/2020-5/2021. Epilepsy was identified using a validated International Classification of Disease (ICD) and antiseizure medicationbased case definition. Univariate comparisons were calculated using Chi-square, Fisher's exact, Mann-Whitney U, or Student's t-tests. Multivariable logistic regression models were generated to examine factors associated with mortality, discharge disposition and length of stay (LOS).
We identified 5384 older adults admitted with COVID-19 of whom 173 (3.21 %) had epilepsy. Mean age was significantly lower in those with (75.44, standard deviation (SD): 7.23) compared to those without epilepsy (77.98, SD: 8.68, p = 0.007). Older adults with epilepsy were more likely to be ventilated (35.84 % vs. 16.18 %, p < 0.001), less likely to be discharged home (21.39 % vs. 43.12 %, p < 0.001), had longer median LOS (13 days vs. 8 days, p < 0.001), and had higher in-hospital death (35.84 % vs. 28.29 %, p = 0.030) compared to those without epilepsy. Epilepsy in older adults was associated with increased odds of in-hospital death (adjusted odds ratio (aOR), 1.55; 95 % CI 1.12-2.14, p = 0.032), non-routine discharge disposition (aOR, 3.34; 95 % CI 2.21-5.03, p < 0.001), and longer LOS (46.46 % 95 % CI 34 %-59 %, p < 0.001).
In models that adjusted for multiple confounders including comorbidity and age, our study found that epilepsy was still associated with higher in-hospital mortality, longer LOS and worse discharge dispositions in older adults with COVID-19 higher in-hospital mortality, longer LOS and worse discharge dispositions in older adults with COVID-19. This work reinforces that epilepsy is a risk factor for worse outcomes in older adults admitted with COVID-19. Timely identification and treatment of COVID-19 in epilepsy may improve outcomes in older people with epilepsy.
2019 年冠状病毒病(COVID-19)在老年人中死亡率和发病率很高,尤其是那些有基础疾病的老年人。很少有研究调查神经系统疾病如何影响患有 COVID-19 的老年人。我们旨在比较有和没有癫痫的老年人的住院期间结局,包括死亡率。
这项在纽约一个大型多中心卫生系统中进行的回顾性研究纳入了 2020 年 3 月至 2021 年 5 月期间因 COVID-19 入院的年龄≥65 岁的老年人,无论是否患有癫痫。使用验证后的国际疾病分类(ICD)和抗癫痫药物的病例定义来确定癫痫。使用卡方检验、Fisher 精确检验、Mann-Whitney U 检验或学生 t 检验进行单变量比较。生成多变量逻辑回归模型来检查与死亡率、出院去向和住院时间(LOS)相关的因素。
我们确定了 5384 名因 COVID-19 入院的老年人,其中 173 名(3.21%)患有癫痫。与没有癫痫的患者相比,有癫痫的患者的平均年龄明显较低(75.44,标准差(SD):7.23 岁比 77.98,SD:8.68 岁,p=0.007)。有癫痫的老年人更有可能接受通气治疗(35.84%比 16.18%,p<0.001),更不可能出院回家(21.39%比 43.12%,p<0.001),中位 LOS 更长(13 天比 8 天,p<0.001),住院期间死亡率更高(35.84%比 28.29%,p=0.030)。与没有癫痫的患者相比,老年人癫痫与住院期间死亡的几率增加相关(调整后的优势比(aOR),1.55;95%CI 1.12-2.14,p=0.032),非常规出院去向(aOR,3.34;95%CI 2.21-5.03,p<0.001)和更长的 LOS(46.46%95%CI 34%-59%,p<0.001)。
在调整了多种混杂因素(包括合并症和年龄)的模型中,我们的研究发现,癫痫与 COVID-19 老年患者的住院期间死亡率更高、LOS 更长和出院去向更差相关。COVID-19 癫痫患者的早期识别和治疗可能会改善老年癫痫患者的结局。